Examining the Science of Aging: Geo-Protective Molecules and the Search for Reliable Biomarkers

The Ongoing Quest for Aging Biomarkers

When it comes to assessing the impact of interventions aimed at slowing or reversing biological aging, the field lacks definitive biomarkers comparable to those available for monitoring conditions like high cholesterol or diabetes. While humans can reliably visually estimate biological age based on factors like wrinkles and muscle mass, the goal is to identify precise molecular signatures in blood or other biosamples that reflect biological youth versus advanced aging at the individual level.

So-called “epigenetic clocks” attempt to measure biological age based on age-related chemical changes to DNA, but current versions show inconsistent performance across populations and lack causal validation in longitudinal studies. There are also concerns around commercial epigenetic clocks being sold directly to consumers without strong clinical evidence they accurately measure biological age.

Prioritizing Functional Outcomes

Functional biomarkers like organ health and exercise capacity provide tangible indications of future health span, while blood biomarkers remain a work in progress. Improvements across functional outcomes like VO2 max, cardiovascular efficiency, strength, and metabolic markers should give confidence an intervention is yielding meaningful benefits.

Some lifespan experiments in animal models incorporate functional biomarkers like tissue pathology at the end of life. However human trials generally lack access to such definitive endpoints, making evaluation more challenging.

Study Limitations Impact Confidence in Anti-Aging Molecules

A variety of compounds shown to extend lifespan in lab animals are positioned as potential human anti-aging molecules but generally lack causal validation. Human trials mostly rely on surrogate endpoints or short-term changes in putative aging biomarkers of uncertain predictive value for long-term outcomes.

Animal models also have significant limitations. Lifespan studies are rare, sample sizes tend to be small, and findings often aren’t replicated. Environment and genetics differ substantially from humans. Even similar species like non-human primates aren’t ideal model organisms for the aging process.

NAD Biology and Precursors NR and NMN

The NAD molecule and its precursors NR and NMN modulate sirtuin gene pathways and other regulatory processes implicated in aging. But human trials are at early stages, with unanswered questions around optimal dosing, long-term safety, and real-world impacts on function or disease risk.

Some are optimistic the limited positive findings to date will scale with larger, longer studies. Others argue any benefits could derive primarily from correcting NAD deficiency rather than fundamentally slowing normal aging. So evidence remains far too preliminary to support general use.

Evidence for Rapamycin and Metformin Differs

In contrast to NAD, the mTOR inhibitor rapamycin has more causal evidence linking it to lifespan extension in animal models. But human studies focus on short-term impacts on aging biomarkers and risk factors rather than clinical endpoints.

The diabetes medication metformin may also influence aging mechanisms beyond glucose control. While observational data associate it with lower mortality, causality requires confirmation in ongoing trials.

So while neither molecule has definitive clinical validation yet, their evidence bases differ substantially from emerging NAD precursors where key animal and human data remain lacking.

Ongoing Challenges in Human Validation

Ultimately, predicting lifespan impact in humans based on model organism studies remains highly speculative. But researchers hope further developing aging biomarkers, functional outcomes, and large patient registries will strengthen future clinical trials.

In the meantime, claims around anti-aging outcomes for commercial products based on preliminary data deserve ample skepticism from both physicians and consumers.

Progress measuring and influencing biological age won’t be linear, but greater scientific rigor combined with patience and humility will serve the field best in improving lives through this important work.